Tyrosine Kinases as Druggable Targets in Cancer最新文献

Introductory Chapter: Tyrosine Kinases as Drug Targets in Cancer Treatment 导论:酪氨酸激酶作为肿瘤治疗的药物靶点

Tyrosine Kinases as Druggable Targets in Cancer Pub Date : 2019-09-25 DOI: 10.5772/intechopen.86511

H. Ren

引用次数: 0

Noncoding RNAs as Predictive Biomarkers of Therapeutic Response to Tyrosine Kinase Inhibitors in Metastatic Cancer 非编码rna作为转移性癌症对酪氨酸激酶抑制剂治疗反应的预测性生物标志物

Tyrosine Kinases as Druggable Targets in Cancer Pub Date : 2019-04-24 DOI: 10.5772/INTECHOPEN.86082

J. Kováčová, O. Slabý

引用次数: 0

Non-receptor Tyrosine Kinases Role and Significance in Hematological Malignancies 非受体酪氨酸激酶在血液系统恶性肿瘤中的作用和意义

Tyrosine Kinases as Druggable Targets in Cancer Pub Date : 2019-03-15 DOI: 10.5772/INTECHOPEN.84873

A. Azevedo, S. Silva, J. Rueff

引用次数: 8

JAK, an Oncokinase in Hematological Cancer 血液肿瘤中的一种癌激酶JAK

Tyrosine Kinases as Druggable Targets in Cancer Pub Date : 2019-02-15 DOI: 10.5772/INTECHOPEN.84177

Carlota Recio, Haidée Aranda-Tavío, Miguel Guerra-Rodríguez, M. Mirecki-Garrido, P. Martín-Rodríguez, B. Guerra, L. Fernández-Pérez

{"title":"JAK, an Oncokinase in Hematological Cancer","authors":"Carlota Recio, Haidée Aranda-Tavío, Miguel Guerra-Rodríguez, M. Mirecki-Garrido, P. Martín-Rodríguez, B. Guerra, L. Fernández-Pérez","doi":"10.5772/INTECHOPEN.84177","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.84177","url":null,"abstract":"Janus kinases (JAKs) play an essential role in the regulation of cytokine signaling. They control cell survival, proliferation, differentiation, immune response, and hematopoiesis. Deregulation of JAK signaling has been associated to the pathogenesis of numerous immune-inflammatory diseases, hematological malignancies, and solid tumors. Thus, JAK proteins have emerged as attractive therapeutic targets in the last decade. The discovery of the gain-of-function JAK2 mutation (JAK2 V617F) as the main cause of polycythemia vera—a chronic myeloproliferative syndrome— led to the development of the JAK inhibitor ruxolitinib. This key finding opened the door to the search for new therapeutic agents able to suppress the constitutive activation of JAK signaling in hematological cancers and other tumors. However, given the conserved nature of the kinase domain among JAK family members, and the interrelated roles of JAK kinases in many physiological processes, including hematopoiesis and immunity, the broad usage of JAK inhibitors in hematology is challenged by their narrow therapeutic window. Novel therapies are, therefore, needed. This chapter focuses on the understanding of the complex signaling of JAK proteins in cancerous cells, the various JAK aberrations implicated in myeloproliferative neoplasms, leukemia, and lymphoma, and the clinically available JAK inhibitors in cancer therapy.","PeriodicalId":174672,"journal":{"name":"Tyrosine Kinases as Druggable Targets in Cancer","volume":"284 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116371949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies 酪氨酸激酶抑制剂治疗癌症:疗效、局限性和未来策略

Tyrosine Kinases as Druggable Targets in Cancer Pub Date : 2019-01-21 DOI: 10.5772/INTECHOPEN.82513

Venice Wing-Tung Ho, H. Tan, Ning Wang, Yibin Feng

引用次数: 10